Replies to post #184902 on Biotech Values

[DewDiligence]

CRME +24%/AH on dalbavancin ex-US commercialization deal with AGN:

http://finance.yahoo.com/news/cardiome-allergan-announce-xydalba-dalbavancin-201500978.html

Cardiome will provide Allergan with a staggered upfront payment totalling US$13 million and will provide Allergan additional milestone payments and royalties based upon commercial achievements and sales of XYDALBA™. Additional terms of the agreement were not disclosed.